Embed Size (px)
DESCRIPTION
Citation preview
Corporate Overview
|
Corporate Overview
BIONITY is an independent consulting firm focusing on complex valuation, financial-, IPR consultancy, market analysis and licensing.
We provide our services mainly to biotech-, pharma-, medtech companies, life sciences focused investors and academic research institutions.
Our office is located in Budapest, Hungary, with a broad activity in CEE.
Budapest
|
Our Industry Focus: Life Sciences
PreClinical / Clinical Stage Drug Development Projects Platform & Drug Delivery Technologies
Medical Device Developments Diagnostics & Analytical Technologies
CROs & SMOs
BioInformatics
Development of API & Biological Manufacturing Capacities
1.
2.
3.
4.
|
Partnerships and Membership
eckel & partners exhibit decades of local and international industry experience on executive level. eckel & partners provides pragmatic business development and marketing services to Pharma, Biotech and other health care companies. Their team and associates are transaction-orientated and help our clients to create incremental value through Partnering and M&A on an international scale.
www.eckelpartners.com
Cogito Consuiting is an IPR and technology valuation specialist consulting firm located in Budapest. Its expertise include novelty, patentability, FTO analysis and strategic IPR consulting. Cogito is also supporting its clients with evaluation of the market potential of new technologies.
www.cogitoconsuling.eu
The Hungarian Biotechnology Association (HBA) was established by Hungary's leading human biotechnology companies with the aim of promoting the development and representation of the Hungarian biotechnology sector. www.hungariabiotech.org
|
|
Technology Assessment A combination of patentability, freedom to operate and market opportunities has to be taken into account when an invention originating from university research is examined for a decision on commercialization. We are supporting TTOs and Incubator Houses in the initial assessment of novelty, market potential, in the elaboration of a business strategy and in the development all the way to involve Seed Money and/or Business Angels into the project.
Novelty and patentability analysis Freedom-to-operate analysis Evaluation of market potential IP Analysis and IPR Strategy
|
Pipeline Review and Valuations
Our expertise in financial valuation combined with our strategic partners - specialized in legal, regulatory affairs & IPR - opens the door to a comprehensive and sound review of your pipeline.
Value of each project scenario Value of pipeline Risk profile of pipeline Sales forecasts of each project (worst case, base case, best case) Value development of each project Value development of the pipeline Scenario analysis
|
Investment & Market Analysis
We support you with our valuation and due diligence to get this insight before you commit your money into new R&D projects. A market analysis can be combined with competitor and product surveillance.
SWOT, Five Forces Analysis of your company and projects Terry Hill Analysis of operations Desk researches about competitive landscape and market potentials Analysis of the Probabilities of Success Evaluation of Peak Sales dynamics, volatility, elasticity with different scenarios
|
Creating Spin-Outs
Supporting holding companies and TTOs to make ROI on promissing project and create a realistic business model and achievable plans. Setting-up transparent business terms is fundamental for the proper functioning of outperforming growth of Spin-outs.
Specific factors to the Founders, Shareholders, Inventors. Legal advice on ownership structure of the Spin-out company Involving external partners, Coaches, Venture advisors into Spin-off
|
Raising Capital
Our strong network with Life Sciences focused VCs , CVCs and HNWIs is prerequested to reach and meet suitable investor(s) corresponding to your financial needs, pipeline and stage of development.
Reviewing the Teaser and Company Presentation Elaboration of Mid-term individual financial Strategies Defining and continously updateing the „Investors List” Planning and organizing one-on-one meetings with potential investors Structuring the Term Sheet and assisting on the Due Diligence process Corporate restructuring and Corporate governance related to deals
|
Financial Planning The discount rate for the valuation is elaborated for each company individually based on our sound model that takes into account the development stage of the pipeline projects, IP positions, indications, risk, operating costs and the strategy of the Company.
CashFlow Analysis Profit and Loss Statements (P&L) Risk-Adjusted Net Present Value Calculations (rNPV) Real-Options Valutions (ROV) Deal-Sourcing and Pre-Selection Services for professional Investors
|
Licensing and Partnering For a BioPharma company, securing IPR and exploiting such rights by licensing/partnering constitute some of the most fundamental aspects of the business. We help define which rights should be licensed and what type of license should be granted. Developing Licensing Strategy (Upfront, Milestone, Royalty payments) License contract value for licensee and licensor (rNPV, Real Options) IRR for licensee and licensor (rNPV and Real Options) Value share between licensor and licensee Identifying and contacting potential license partners Implementing, negotiating and managing License-In & Out deals Advising on Term Sheets and Licensing Agreements
|
FDI Promotion
Hungarian life sciences sector is characterized with highly skilled workforce, stable political and regulatory system & strong governmental commitment. Whether it is a specialized R&D unit or a large greenfield manufacturing plant, we help you to find the rigth local partnes and ideal location. Market intelligence; Feasibility studies on foreign direct investments; Academic match-making; Site Evaluation and pre-selection services; Negotiation with investment promotion agencies; Supporting investors to obtain setting-up permissions on fast-track;
|
Professional Background
Before founding Bionity R&D Investment Advisors in 2007, he was the director of the CEE activities at PCA Capital Advisors (2005-2007), a Frankfurt based corporate finance butique focusing on biotechnology and ICT financing. Before he held the position of “Head of Priority Sectors” at the Hungarian Investment and Trade Development Agency, ITDH (2002-2005). He is fluent in English and French. He is the Board Member of the Hungarian Biotechnology Association and member of the SME Platform of EuropaBio.
He is currently a fellow at the globally renowned Biotechnology MBA program of Instituto de Empresa Business School (Madrid, Spain) and Harvard Business School (Boston, MA). He has been graduating in economics at Budapest University of Economic Science and Administration with major in entrepreneurship, and also obtained Master degree in “European Studies” at the same institution.
Marcell Veidner Managing director
+3620.284.9662 [email protected]
